UA83202C2 - Фенилзамещенные пиперидины для использования в качестве активаторов рапп - Google Patents
Фенилзамещенные пиперидины для использования в качестве активаторов раппInfo
- Publication number
- UA83202C2 UA83202C2 UAA200505008A UA2005005008A UA83202C2 UA 83202 C2 UA83202 C2 UA 83202C2 UA A200505008 A UAA200505008 A UA A200505008A UA 2005005008 A UA2005005008 A UA 2005005008A UA 83202 C2 UA83202 C2 UA 83202C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cholesterol
- phenyl substituted
- piperidine compounds
- substituted piperidine
- compounds
- Prior art date
Links
- 239000012190 activator Substances 0.000 title abstract 2
- 101150014691 PPARA gene Proteins 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 2
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108010023302 HDL Cholesterol Proteins 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 108010028924 PPAR alpha Proteins 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Описываются активаторы РАПП альфа, фармацевтические композиции, которые содержат такие соединения, и применение таких соединений для увеличения уровней некоторых липидов в плазме, включая липопротеин высокой плотности-холестерол, и снижение уровней некоторых других липидов в плазме, таких как ЛНП-холестерол и триглицеридов, и соответственно для лечения заболеваний, которые усложняются низкими уровнями ЛВП-холестерола и/или высокими уровнями ЛНП-холестерола и триглицеридами, таких как атеросклероз и кардиоваскулярные заболевания, у млекопитающих, включая людей.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42950602P | 2002-11-26 | 2002-11-26 | |
| PCT/IB2003/005235 WO2004048334A1 (en) | 2002-11-26 | 2003-11-14 | Phenyl substituted piperidine compounds for use as ppar activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA83202C2 true UA83202C2 (ru) | 2008-06-25 |
Family
ID=32393563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200505008A UA83202C2 (ru) | 2002-11-26 | 2003-11-14 | Фенилзамещенные пиперидины для использования в качестве активаторов рапп |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7199243B2 (ru) |
| EP (1) | EP1567493B1 (ru) |
| JP (1) | JP4029091B2 (ru) |
| KR (2) | KR100875318B1 (ru) |
| CN (1) | CN100439337C (ru) |
| AR (1) | AR042131A1 (ru) |
| AT (1) | ATE425966T1 (ru) |
| AU (1) | AU2003276596B8 (ru) |
| BR (1) | BR0316521A (ru) |
| CA (1) | CA2507465C (ru) |
| CO (1) | CO5570701A2 (ru) |
| DE (1) | DE60326752D1 (ru) |
| DK (1) | DK1567493T3 (ru) |
| EA (1) | EA008928B1 (ru) |
| ES (1) | ES2321509T3 (ru) |
| GT (1) | GT200300258A (ru) |
| HR (1) | HRP20050437A2 (ru) |
| IS (1) | IS7816A (ru) |
| MA (1) | MA27532A1 (ru) |
| MX (1) | MXPA05005583A (ru) |
| NL (1) | NL1024881C2 (ru) |
| NO (1) | NO20052921L (ru) |
| NZ (1) | NZ539546A (ru) |
| PE (1) | PE20040699A1 (ru) |
| PL (1) | PL378268A1 (ru) |
| PT (1) | PT1567493E (ru) |
| SI (1) | SI1567493T1 (ru) |
| TN (1) | TNSN05146A1 (ru) |
| TW (1) | TW200424172A (ru) |
| UA (1) | UA83202C2 (ru) |
| UY (1) | UY28097A1 (ru) |
| WO (1) | WO2004048334A1 (ru) |
| ZA (1) | ZA200503104B (ru) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003276596B8 (en) * | 2002-11-26 | 2009-03-05 | Pfizer Products Inc. | Piperidine compounds useful as PPAR activators |
| AU2005247164B2 (en) * | 2004-05-25 | 2008-11-27 | Pfizer Products Inc. | Specific PPAR agonists for treating negative energy balance |
| AU2005247172A1 (en) * | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Use of PPAR agonists to treat ruminants |
| CN101014595A (zh) * | 2004-08-11 | 2007-08-08 | 杏林制药株式会社 | 新型环状氨基苯甲酸衍生物 |
| CA2590533C (en) * | 2004-11-23 | 2010-09-07 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
| WO2006101108A1 (ja) * | 2005-03-23 | 2006-09-28 | Kyorin Pharmaceutical Co., Ltd. | 新規環状アミノフェニルアルカン酸誘導体 |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| CN101296914B (zh) * | 2005-08-26 | 2012-07-18 | 盐野义制药株式会社 | 具有ppar激动活性的衍生物 |
| US9173875B2 (en) * | 2006-04-11 | 2015-11-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists |
| ATE496043T1 (de) * | 2006-12-01 | 2011-02-15 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren |
| EP2178534A4 (en) * | 2007-07-17 | 2011-03-30 | Merck Sharp & Dohme | SOLUBLE EPOXYHYDROLASE HEMMER, COMPOSITIONS WITH SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH |
| AU2008275891B2 (en) * | 2007-07-19 | 2013-10-10 | H.Lundbeck A/S | 5-membered heterocyclic amides and related compounds |
| TW201006816A (en) | 2008-05-15 | 2010-02-16 | Organon Nv | Hexafluoroisopropanol derivatives |
| FR2935511B1 (fr) | 2008-08-28 | 2010-12-10 | Oberthur Technologies | Procede d'echange de donnees entre deux entites electroniques |
| FR2935510B1 (fr) | 2008-08-28 | 2010-12-10 | Oberthur Technologies | Procede d'echange de donnees entre deux entites electroniques |
| UA107938C2 (en) | 2009-08-12 | 2015-03-10 | Syngenta Participations Ag | Heterocycles with microbicidal properties |
| US8716482B2 (en) * | 2009-09-25 | 2014-05-06 | Merck Sharp & Dohme Corp. | Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes |
| TWI513695B (zh) * | 2009-10-27 | 2015-12-21 | Merck Sharp & Dohme | （１，１，１，３，３，３－六氟－２－羥基丙－２－基）苯基衍生物 |
| EP2363825B1 (fr) | 2010-03-04 | 2016-04-27 | Inside Secure | Procédé pour conduire une transaction au moyen d'un dispositif NFC |
| JP2014513923A (ja) | 2011-03-04 | 2014-06-19 | ファイザー・インク | Ｅｄｎ３様ペプチドおよびその使用 |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| RU2615769C2 (ru) * | 2015-07-29 | 2017-04-11 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Уфимский Государственный Университет Экономики И Сервиса" | Средство для ингибирования фермента альфа-амилазы |
| US20220411372A1 (en) * | 2019-09-20 | 2022-12-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small-molecule inhibitors for the b-catenin/b-cell lymphoma 9 protein-protein interaction |
| CN116162056A (zh) * | 2021-11-24 | 2023-05-26 | 上海医药工业研究院 | β-catenin/BCL9蛋白-蛋白相互作用的小分子抑制剂及其应用 |
| WO2024022521A1 (zh) * | 2022-07-28 | 2024-02-01 | 南通环聚泰生物科技有限公司 | 靶向BCL9/β-连环蛋白互相作用的小分子化合物 |
| WO2024145931A1 (zh) * | 2023-01-06 | 2024-07-11 | 上海医药工业研究院有限公司 | β-catenin/BCL9蛋白蛋白相互作用的小分子抑制剂及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2025518A1 (ru) * | 1969-06-05 | 1970-12-10 | ||
| US4476311A (en) * | 1980-03-12 | 1984-10-09 | The Purdue Frederick Company | Analgesic 4-carboxy-pyrrolidin-2-one compound |
| EP0077607A1 (en) * | 1981-09-17 | 1983-04-27 | Beecham Group Plc | N-substituted 3-aryl piperidines and derivatives thereof |
| EP0115607A1 (de) * | 1983-01-04 | 1984-08-15 | MERCK PATENT GmbH | Tetrahydrocarbazolderivate |
| GB9027023D0 (en) * | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| US5274143A (en) * | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| AU2869092A (en) | 1991-10-11 | 1993-05-03 | Smithkline Beecham Corporation | Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production |
| WO1993012086A1 (fr) * | 1991-12-11 | 1993-06-24 | Ss Pharmaceutical Co., Ltd. | Derive d'arylamide |
| JPH05255089A (ja) * | 1991-12-18 | 1993-10-05 | Sanwa Kagaku Kenkyusho Co Ltd | 抗ウイルス剤 |
| JP3233991B2 (ja) * | 1992-06-26 | 2001-12-04 | 株式会社ソフィア | 遊技機 |
| ES2156120T3 (es) * | 1992-12-08 | 2001-06-16 | Ss Pharmaceutical Co | Derivados arilamidicos. |
| AU3138595A (en) | 1994-07-20 | 1996-02-16 | Acea Pharmaceuticals, Inc. | Haloperidol analogs and the use thereof |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| JPH09312086A (ja) * | 1996-05-22 | 1997-12-02 | Matsushita Electric Ind Co Ltd | 光ディスク再生システム、光ディスク再生方法および光ディスク |
| WO1998005331A2 (en) | 1996-08-02 | 1998-02-12 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
| IT1286497B1 (it) * | 1996-11-20 | 1998-07-15 | Italfarmaco Sud Spa | Difosfine di tipo misto eteroariliche-ariliche come leganti chirali, relativi complessi con metalli di transizione e impiego di detti |
| ES2281146T3 (es) * | 1997-12-19 | 2007-09-16 | MERCK & CO., INC. | Ariltiazolidindionas utiles como compuestos terapeuticos. |
| EP0952154B1 (en) * | 1998-04-16 | 2004-08-18 | Pfizer Products Inc. | N-acyl and N-aroyl aralkyl amides |
| US6376494B1 (en) * | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
| HN1999000149A (es) | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
| GB9822473D0 (en) | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
| US6303637B1 (en) * | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
| CA2324330A1 (en) * | 1999-11-08 | 2001-05-08 | Ssp Co., Ltd. | 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same |
| US20020045613A1 (en) | 2000-04-27 | 2002-04-18 | Heinz Pauls | 1-aroyl-piperidinyl benzamidines |
| WO2001085716A1 (en) | 2000-05-11 | 2001-11-15 | Kyowa Hakko Kogyo Co., Ltd | 2-piperidone compounds for the treatment of cancer |
| KR100858642B1 (ko) | 2000-05-22 | 2008-09-17 | 아벤티스 파마슈티칼스 인크. | 트립타제 억제제로서 사용하기 위한 아릴메틸아민 유도체 |
| AU2001211337A1 (en) | 2000-10-06 | 2002-04-15 | Smithkline Beecham Plc | Process for the preparation of aryl-piperidine carbinols and intermediates thereof |
| CA2424979A1 (en) | 2000-10-12 | 2003-04-04 | Ssp Co., Ltd. | 2,2-diphenylbutanamide derivatives and medicines containing the same |
| JP2002173426A (ja) | 2000-12-05 | 2002-06-21 | Ss Pharmaceut Co Ltd | 血糖低下剤 |
| WO2002064139A1 (en) * | 2001-02-15 | 2002-08-22 | Neurosearch A/S | Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity |
| CA2438551A1 (en) * | 2001-02-15 | 2002-08-22 | Pfizer Products Inc. | Ppar agonists |
| AU2003276596B8 (en) * | 2002-11-26 | 2009-03-05 | Pfizer Products Inc. | Piperidine compounds useful as PPAR activators |
-
2003
- 2003-11-14 AU AU2003276596A patent/AU2003276596B8/en not_active Ceased
- 2003-11-14 UA UAA200505008A patent/UA83202C2/ru unknown
- 2003-11-14 SI SI200331552T patent/SI1567493T1/sl unknown
- 2003-11-14 CA CA002507465A patent/CA2507465C/en not_active Expired - Fee Related
- 2003-11-14 MX MXPA05005583A patent/MXPA05005583A/es active IP Right Grant
- 2003-11-14 DK DK03811832T patent/DK1567493T3/da active
- 2003-11-14 HR HR20050437A patent/HRP20050437A2/hr not_active Application Discontinuation
- 2003-11-14 WO PCT/IB2003/005235 patent/WO2004048334A1/en not_active Ceased
- 2003-11-14 ES ES03811832T patent/ES2321509T3/es not_active Expired - Lifetime
- 2003-11-14 KR KR1020077012457A patent/KR100875318B1/ko not_active Expired - Fee Related
- 2003-11-14 PT PT03811832T patent/PT1567493E/pt unknown
- 2003-11-14 CN CNB200380104275XA patent/CN100439337C/zh not_active Expired - Fee Related
- 2003-11-14 EA EA200500629A patent/EA008928B1/ru not_active IP Right Cessation
- 2003-11-14 JP JP2004554809A patent/JP4029091B2/ja not_active Expired - Fee Related
- 2003-11-14 PL PL378268A patent/PL378268A1/pl not_active Application Discontinuation
- 2003-11-14 NZ NZ539546A patent/NZ539546A/en unknown
- 2003-11-14 KR KR1020057009389A patent/KR100760055B1/ko not_active Expired - Fee Related
- 2003-11-14 BR BR0316521-3A patent/BR0316521A/pt not_active IP Right Cessation
- 2003-11-14 DE DE60326752T patent/DE60326752D1/de not_active Expired - Lifetime
- 2003-11-14 EP EP03811832A patent/EP1567493B1/en not_active Expired - Lifetime
- 2003-11-14 AT AT03811832T patent/ATE425966T1/de not_active IP Right Cessation
- 2003-11-24 US US10/720,942 patent/US7199243B2/en not_active Expired - Fee Related
- 2003-11-24 AR ARP030104332A patent/AR042131A1/es unknown
- 2003-11-25 TW TW092133036A patent/TW200424172A/zh unknown
- 2003-11-25 PE PE2003001197A patent/PE20040699A1/es not_active Application Discontinuation
- 2003-11-26 GT GT200300258A patent/GT200300258A/es unknown
- 2003-11-26 NL NL1024881A patent/NL1024881C2/nl not_active IP Right Cessation
- 2003-11-26 UY UY28097A patent/UY28097A1/es not_active Application Discontinuation
-
2005
- 2005-04-18 ZA ZA200503104A patent/ZA200503104B/en unknown
- 2005-04-20 IS IS7816A patent/IS7816A/is unknown
- 2005-05-19 CO CO05048657A patent/CO5570701A2/es not_active Application Discontinuation
- 2005-05-26 TN TNP2005000146A patent/TNSN05146A1/fr unknown
- 2005-05-26 MA MA28299A patent/MA27532A1/fr unknown
- 2005-06-15 NO NO20052921A patent/NO20052921L/no not_active Application Discontinuation
-
2007
- 2007-03-30 US US11/694,337 patent/US20070191429A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA83202C2 (ru) | Фенилзамещенные пиперидины для использования в качестве активаторов рапп | |
| AP2002002426A0 (en) | Ppar agonists | |
| TW200630350A (en) | Dibenzyl amine compounds and derivatives | |
| AP2002002427A0 (en) | Ppar compounds. | |
| TW200508222A (en) | Quinoline and quinoxaline compounds | |
| MXPA05012570A (es) | Derivados de tetrahidroisoquinolina como activadores de ppar-a. | |
| TW200736235A (en) | Dibenzyl amine compounds and derivatives | |
| MY121838A (en) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines | |
| MY121405A (en) | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines | |
| TW200611690A (en) | Substituted heteroaryl- and phenylsulfamoyl compounds | |
| ATE301640T1 (de) | Anellierte 4-carboxyamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp-hemmer | |
| CA2282183A1 (en) | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines | |
| BG105428A (en) | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors | |
| TW200610525A (en) | Substituted heteroaryl-and phenylsulfamoyl compounds | |
| MX2009005455A (es) | (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano. | |
| NO20071510L (no) | 4-Amino-substituerte-2-substituerte-1,2,3,4-tetrahydrokinolinforbindelser | |
| EP1594509A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF IRRITABLE COLON SYNDROME AND NON ULCEREUS DYSPEPSIS | |
| TW200738652A (en) | Dibenzyl amine compounds and derivatives | |
| WO2009027785A3 (en) | 1, 3-oxazole derivatives as cetp inhibitors | |
| TW200616964A (en) | Quinoline compounds | |
| MX2007010243A (es) | Compuestos de 1,1,1-trifluoro-3-[(bencil)-(pirimidin-2-il)-amino]- propan-2-ol sustituidos. | |
| UY29123A1 (es) | Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina | |
| DOP2005000182A (es) | Compuestos de 4-amino-sustituido-2-sustituido-1,2,3-tetrahidroquinolina | |
| DOP2002000331A (es) | Compuesto de ppar | |
| UY27158A1 (es) | Compuestos de ppar |